<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000502.v1.p1" parentStudy="phs000502.v1.p1" createDate="2012-05-29" modDate="2012-07-12">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>Laura Pasqualucci, MD</td><td>Institute for Cancer Genetics, Columbia University, New York, NY, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Riccardo Dalla-Favera, MD</td><td>Institute for Cancer Genetics, Columbia University, New York, NY, USA</td></tr>
		<tr><td>Funding Source</td><td>PO1-CA092625</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genome-Wide Analysis of Splenic Marginal Zone Lymphoma</StudyNameEntrez>
	<StudyNameReportPage>Genome-Wide Analysis of Splenic Marginal Zone Lymphoma</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Splenic Marginal Zone Lymphoma (SMZL) is a B-cell malignancy of unknown pathogenesis and thus orphan of targeted therapies. By integrating whole-exome sequencing and copy-number analysis of 8 paired tumor-normal DNAs from patients with SMZL, we show that the typical SMZL exome carries ~30 genetic alterations. Targeted resequencing of selected candidates in an extended panel of 40-117 samples revealed activating mutations of NOTCH2, a gene required for marginal-zone (MZ) development, as the most frequent and SMZL-specific lesion, accounting for approximately 20% of cases. Additional altered genes suggest that deregulation of signaling pathways normally involved in MZ development (NOTCH, NF-kappa B, and B-cell receptor) represents a critical event in SMZL pathogenesis. These findings have direct implications for the treatment of SMZL patients since drugs are available which can target NOTCH as well as other pathways deregulated in this disease.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p><ol> <li>Previously untreated, de novo diagnoses of Splenic Marginal Zone Lymphoma</li> <li>Matched tumor and normal genomic DNA</li></ol> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Fama R, 			Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G,  Messina M, Rinaldi A, Wang J, Agostinelli C, 			Piccaluga PP, Lucioni M, Tabbo F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, 			Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foa R, Dalla-Favera R, Pasqualucci L, 			3Rabadan R, Gaidano G" title="Analysis of the Coding Genome of Spelenic Marginal Zone Lymphoma Reveals Mutational 			Activation of NOTHC2 and Other Pathways Regulating Marginal Zone Differentiation" journal="Journal of Experimental Medicine. 2012, accepted"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Lymphoma, Non-Hodgkin"/>
		<Disease vocab_source="MESH" vocab_term="Lymphoma, B-Cell"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>Laura Pasqualucci, MD</AttName>
			<Institution>Institute for Cancer Genetics, Columbia University, New York, NY, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Riccardo Dalla-Favera, MD</AttName>
			<Institution>Institute for Cancer Genetics, Columbia University, New York, NY, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>PO1-CA092625</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="Institute for Cancer Genetics" url="http://icg.cumc.columbia.edu/"/>
	</StudyURLs>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="CRGM_PUB" longName="Cancer Research and General Methods with Publication Statement"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000502.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000502.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000502.v1.p1" FileName="Pasqualucci_DUC.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Cancer Research and General Methods with Publication Statement</ConsentName>
        <ConsentAbbrev>CRGM_PUB</ConsentAbbrev>
        <UseLimitation>Use of the data is limited to scientific research relevant to the etiology, prevention, treatment, and late complications of treatment of cancer and for the development of applications proposing analytical methods, software, or other research tools. Investigators must state in the Data Access Request their intention to publish or otherwise broadly share any finding from his/her study with the scientific community.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
